May 17th 2024
Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for protein and energy intake!
Study Raises Alarm Over Risk of Chronic Kidney Disease, Rising Obesity Rates in Type 1 Diabetes
January 26th 2022An analysis of data from more than 135k patients with type 1 and type 2 diabetes indicates the age-adjusted rate of chronic kidney disease was greater in type 1 diabetes and also sheds light on the rising rate of obesity in type 1 diabetes.
Nutrition Information Hard to Find, Access for Patients with Kidney Disease
January 19th 2022A recent study published in the Journal of the American Society of Nephrology suggests patients with chronic kidney disease have little access to reliable information related to nutrition for patients with chronic kidney disease.
Deepak Bhatt, MD, MPH: Sotagliflozin Provides Consistent Benefit Across Spectrum of Kidney Function
November 14th 2021Deepak Bhatt, MD, MPH, discusses the results of a pooled analysis of the SOLOIST and SCORED trials assessing effects of sotagliflozin based on baseline eGFR among patients included in the trials.
CLICK Trial: Chlorthalidone Reduces BP in Chronic Kidney Disease and Uncontrolled Hypertension
November 10th 2021Data from the CLICK trial presented at Kidney Week 2021 demonstrates chlorthalidone reduced systolic blood pressure by 11 mmHg over a 12-week treatment period among a patient population with stage 4 CKD and uncontrolled hypertension.
Dapagliflozin Slows Rate of Kidney Function Decline, Regardless of Diabetes Status
November 9th 2021Data from a prespecified analysis of DAPA-CKD presented at Kidney Week 2021 provides insight into the effects of dapagliflozin use on the rate of kidney function decline based on the presence of type 2 diabetes from the trial.
Risk Model Suggests SGLT2 Inhibitors Could Reduce CV, Renal Risk in Type 1 Diabetes
November 8th 2021Using the Steno Type 1 Risk Engine, a team from Denmark conducted a study suggesting SGLT2 inhibition could lower risk of cardiovascular disease and end-stage kidney disease in patients with type 1 diabetes.
FIDELITY: Finerenone Slows CKD Progression Across Full Spectrum of Severity
November 5th 2021Data from the FIDELITY analysis suggests use of finerenone was associated with a significant 20% reduction in end-stage kidney disease as well as reductions in all nonfatal kidney end points included in the study's composite kidney outcome.
Skipped UACR Testing Often Leads to Missed Albuminuria in Patients with Diabetes, Hypertension
August 21st 2021A new meta-analysis by investigators from Johns Hopkins details the prevalence of UACR testing in patient populations at increased risk of albuminuria, suggesting less than 40% of patients with diabetes underwent UACR testing and this figure dropped to less than 5% among patients with hypertension.
BMI Variability Can Predict Negative Outcomes in Chronic Kidney Disease
August 15th 2021An analysis of data from a national health database in South Korea suggests increased BMI variability was linked to a 66% greater risk of mortality and a 19% greater risk of heart attack and stroke in patients with chronic kidney disease.
Weight Fluctuations Could Predict Negative Outcomes in Chronic Kidney Disease
August 12th 2021An analysis of more than 50,000 patients with chronic kidney disease indicates increased BMI variability was tied to increased risk of mortality, need for kidney replacement therapy, and cardiovascular disease events.
Excessive Caffeine Consumption Increases Renal Calcium Clearance, Australian Study Finds
July 27th 2021A study from the University of South Australia assessing the impact of high-dose, short-term caffeine consumption suggests increased consumption could increase renal calcium clearance by 77% in healthy patients.
Dapagliflozin Safe and Effective in Stage 4 Chronic Kidney Disease, DAPA-CKD Analysis Finds
July 20th 2021A prespecified analysis of patients with stage 4 CKD from DAPA-CKD suggests the magnitude of effects seen with dapagliflozin use among these patients was similar to that seen among patients with normal to moderately impaired kidney function from the trial.
FDA Panel Votes Against Roxadustat, Cites Risk of Thrombotic Events
July 16th 2021The subject of a July 15 meeting, the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 13-1 and 12-2 against recommending approval of roxadustat for treatment of anemia in adult patients with chronic kidney disease not on dialysis and on dialysis, respectively.
Finerenone (KERENDIA) Approved for Chronic Kidney Disease Associated with Type 2 Diabetes
July 9th 2021With approval on July 9, finerenone (Kerendia) becomes the first nonsteroidal mineralocorticoid receptor antagonist to receive approval for use in adults with chronic kidney disease associated with type 2 diabetes.
DISCOVER Details Gradual Uptake, Need for Improvement in Prescribing of SGLT2 Inhibitors, GLP-1 RAs
July 2nd 2021Insights from the DISCOVER registry were presented at the American Diabetes Association's 81st Scientific Sessions. Check out our Q&A with study presenter Suzanne Arnold, MD, of St. Luke's Mid America Heart Institute.
ADA 2021: Sotagliflozin Impact in Patients with Type 2 Diabetes Highlighted in Special Session
June 29th 2021While still waiting for regulatory approval, the SCORED and SOLOIST trial have demonstrated the impact of sotagliflozin, a dual SGLT1/2 inhibitor, on patients with type 2 diabetes and chronic kidney disease or heart failure.